We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tryptophan Metabolism in Kidney Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00758537
First Posted: September 25, 2008
Last Update Posted: July 14, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Charite University, Berlin, Germany
  Purpose
Tryptophan metabolism in kidney disease will be investigated in patients with chronic kidney disease stages (ADOQI 3-5). Tryptophan levels and respective catabolites will be assessed under hemodialysis.

Condition
Chronic Kidney Disease

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Charite University, Berlin, Germany:

Primary Outcome Measures:
  • Course of plasma tryptophan level and levels of tryptophan metabolites under standard low-flux hemodialysis. [ Time Frame: does not apply ]

Estimated Enrollment: 80
Study Start Date: January 2007
Estimated Study Completion Date: October 2008
Groups/Cohorts
Patients with chronic kidney disease stage 3
patients with chronic kidney disease stage 4
patients with chronic kidney disease stage 5 (ESRD)
Controls (no kidney disease)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
tertiary care academic center, university hospital
Criteria

Inclusion Criteria:

  • Chronic kidney disease (for > 3months) stages (National Kidney foundation/ADOQI): 3-5

Exclusion Criteria:

  • Signs of infection or systemic inflammation
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00758537


Locations
Germany
Charite University Medicine Berlin
Berlin, Germany, 13353
Sponsors and Collaborators
Charite University, Berlin, Germany
Investigators
Principal Investigator: Petra Reinke, Md PhD Charite University Medicine
  More Information

Responsible Party: Prof. Dr. Petra Reinke MD, Charite UNiversity Medicine Berlin, Germany
ClinicalTrials.gov Identifier: NCT00758537     History of Changes
Other Study ID Numbers: TRY1STU
First Submitted: September 23, 2008
First Posted: September 25, 2008
Last Update Posted: July 14, 2009
Last Verified: July 2009

Keywords provided by Charite University, Berlin, Germany:
Assessment of tryptophan and tryptophan catabolites and IDO-activity in patients with chronic kidney disease

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Tryptophan
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs